In the tumor tissue, DEX treatment significantly reduced the expression of CTP1A and TXNIP, which are involved in reactive oxygen species (ROS)-related regulatory mechanisms associated with NLRP3 inflammasome activation. The gene discussed is TXNIP; the disease is neoplasm.